This ExpertREACT article was originally published on 20 October 2009 following the FDA's approval of Cervarix on 16 October 2009. Scientific analysis and industry positions described reflect the state of knowledge at that date.
Cervarix: a historic FDA approval
On 16 October 2009, GSK announced that the US FDA had approved its bivalent HPV vaccine Cervarix. The approval was significant not only as a step forward for human papillomavirus disease prevention - Cervarix had already been approved in 100 countries and gained WHO prequalification - but also for its implications for vaccine adjuvant science. Cervarix contains 3-O-desacyl-4'-monophosphoryl lipid A (MPL), a novel adjuvant derived from the cell wall of Salmonella minnesota. Until Cervarix's US approval, the only vaccine adjuvant approved in the US market was aluminium salts (alum), which had been in use since the beginning of the century. Merck & Co's competing HPV vaccine Gardasil - approved in the US in 2006 - uses a traditional alum formulation.
The FDA had previously been notably cautious about novel adjuvants due to vaccine safety concerns - a cautiousness reinforced by historical episodes including the withdrawal of Wyeth's Rotashield rotavirus vaccine in 1999 due to intussusception and the Guillain-Barré Syndrome connection with the 1976 "swine flu" vaccination programme. Cervarix had itself not been without controversy, particularly in the UK where a 14-year-old girl died shortly after receiving the vaccine (though not linked to the vaccine). The FDA's decision to approve Cervarix following review of trials in 30,000 girls across 20 countries effectively signalled an evolution in US policy towards novel adjuvants.
Implications for GSK's pipeline and adjuvant strategy
VacZine Analytics noted that GSK had invested an estimated $300m in acquiring Corixa (and with it the MPL technology) in 2005, with approximately 60% of GSK's vaccine pipeline incorporating one of their proprietary MPL-based adjuvant systems. Beyond Cervarix, the company's malaria programme (RTS,S/AS using MPL and QS-21) was advancing towards Phase III, and the H1N1 pandemic had further demonstrated - through the adjuvanted Pandemrix - that novel adjuvants could enable antigen sparing during pandemic manufacturing. The FDA's Cervarix approval was viewed as likely to elevate investment in new adjuvant science across the industry.